MISSISSAUGA, ON, April 30, 2012 /PRNewswire/ - Covalon
Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an
advanced medical technologies company, today announced it will be
presenting its IV ClearTM line of antimicrobial clear
silicone adhesive vascular access securement dressings from
April 30th to May 2nd at the 2012 Infusion Nurses
Society Annual Convention & Industrial Exhibition in
Las Vegas ("INS").
"Our team is extremely excited to present our newest products
that are designed to address the growing need for infection
control, including Catheter Related Blood Stream Infections
(CRBSI), for which the Center for Disease Control (CDC) calls one
of the most deadly and costly threats to patient safety at this
year's INS meeting," said Brian
Pedlar, Covalon's Chief Executive Officer. "We are looking
forward to introducing our new line-up of products to our growing
domestic and international distribution channels and to medical
product companies who are looking to license breakthrough new
products."
In support of this breakthrough technology, Covalon's Dr.
Liu Yang will present: A Novel
Antimicrobial Clear Silicone Dressing with Chlorhexidine and
Silver at the INS poster sessions. This data demonstrates the
combined benefits of IV Clear's antimicrobial efficacy and patient
friendly silicone adhesive, which for the first time ever is
available within one intuitive dressing system.
The INS convention provides Covalon with the perfect opportunity
to showcase its infusion care related products to 1,500 infusion
nurses from 30 and close to 100 leading manufacturers, wholesalers
and distributors.
Covalon will also be showcasing new medical device coatings,
including its lubricious and antimicrobial coated catheters, which
utilize its patented CovaCoat™ technology. These exciting new
products will be available for license or distribution, following
regulatory clearance.
To learn more about Covalon's products and services, please
visit us at booth 227 in the Rio All-Suite Hotel & Casino from
April 30th to May 2nd or contact Brian Pedlar, CEO, Covalon Technologies Ltd. at
bpedlar@covalon.com.
About Covalon
Covalon Technologies Ltd. researches, develops and commercializes
new healthcare technologies that help save lives around the world.
Covalon's patented technologies, products and services address the
advanced healthcare needs of medical device companies, healthcare
providers and individual consumers. Covalon's technologies are used
to prevent, detect and manage medical conditions in specialty areas
such as wound care, tissue repair, infection control, disease
management, medical device coatings and biocompatibility. To learn
more about Covalon, visit our website at www.covalon.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or
implied in the forward-looking statements. Many risks are inherent
in the industry; others are more specific to the Company. Investors
should consult the Company's ongoing quarterly filings for
additional information on risks and uncertainties relating to these
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements
whether as a result of new information, further events or
otherwise.
SOURCE Covalon Technologies Ltd.